Erudio Healtherudio.com
Drug
Bempegaldesleukin trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying bempegaldesleukin: PIVOT-09. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| PIVOT-09 NCT03729245 · Nektar Therapeutics | previously untreated advanced clear cell renal cell carcinoma | Phase 3 | 27 | 8 | Focused | Oct 30, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| PIVOT-10 NCT03785925 · Nektar Therapeutics FocusedView → | cisplatin-ineligible locally advanced or metastatic urothelial cancer | Phase 2 | Focused | View | |||
| NCT04209114 NCT04209114 · Bristol-Myers Squibb FocusedView → | cisplatin-ineligible muscle-invasive bladder cancer | Phase 3 | Focused | View | |||